COLGATE PALMOLIVE COCL
COLGATE PALMOLIVE CO Financial Overview 2020–2024
Colgate-Palmolive commanded a staggering 10.0% increase in net selling prices during FY2023, proving its core consumer staples can absorb massive inflation without destroying demand. The company is successfully leveraging this extreme pricing power, alongside the rapid expansion of its Hill's Pet Nutrition segment, to shield profitability and compound earnings. Despite a 2.0% volume decline in FY2022, this overarching strategy allowed the business to expand its gross margin to 60.5% by FY2024, effectively neutralizing multi-year supply chain and raw material shocks.
Revenue steadily grew from $16.47 billion in FY2020 to $20.10 billion in FY2024. This expansion was heavily anchored by pet care, with the Hill's division posting a 15.5% net sales increase in FY2023 and continuing to drive top-line momentum with a 3.8% jump in Q2 2025. Management consistently funneled this operational cash back to investors, deploying $1.79 billion for dividends and $1.74 billion for share repurchases throughout FY2024. This steady capital return program reduced the outstanding float from 0.85 billion shares at the end of FY2020 to 0.81 billion shares by the close of FY2024, pushing annual earnings to $3.51 per share. Entering Q1 2025, the board authorized a new $5 billion repurchase initiative and raised the quarterly dividend to $0.52, signaling sustained confidence in the company's ability to generate cash.
Recent Developments (Q2 and Q3 2025)
Colgate-Palmolive launched a Strategic Growth and Productivity Program projected to incur up to $300 million in pre-tax charges through 2028. The company also expanded its pet portfolio by acquiring Prime100 for $301 million. In Q3 2025, net sales grew to $5.131 billion, driven by pricing actions that offset volume declines. However, higher raw material costs compressed the gross profit margin to 59.4%, down from 61.1% a year earlier, and pushed operating profit down 1% to $1.059 billion. To optimize capital structure, the business issued €600,000,000 in 3.250% Senior Notes in November 2025.
Bulls highlight sustained top-line growth and a $2.56 billion stock repurchase during Q2 2025, which supported a Q3 2025 EPS rise to $0.91. Bears warn that persistent cost inflation is directly shrinking margins alongside falling consumer volumes. Trading at 22.0x earnings as of 2025-10-30, the valuation leaves little room for continued operational contraction.
What to watch: margin stabilization from the new productivity program; further volume erosion tied to ongoing pricing actions.
Rev
$20.10B
FY2024
NI
$2.89B
FY2024
EPS
$3.53
FY2024
OCF
$4.11B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
COLGATE PALMOLIVE CO 8-K Report, Financial Results (Jan 30, 2026)
Colgate-Palmolive Company (CL) has filed an 8-K report on January 30, 2026, to announce its financial results for the quarter and full year ended December 31, 2025. The core of this filing is the press release (Exhibit 99) containing these results, which provides investors with key performance metrics and financial condition updates. While the specific details of the earnings are not included in the 8-K text itself, this filing serves as the official notification and incorporation of that information by the company into its SEC disclosures.
COLGATE PALMOLIVE CO 8-K Report, Corporate Update (Nov 10, 2025)
Colgate-Palmolive Company (CL) has filed an 8-K report detailing a significant debt financing transaction. On November 3, 2025, the company entered into an underwriting agreement for the issuance and sale of €600,000,000 of 3.250% Senior Notes due 2035. This offering was made under the company's existing automatic shelf registration statement on Form S-3. These notes were issued on November 10, 2025, under an indenture dated November 15, 1992. The underwriting agreement includes standard provisions for representations, warranties, covenants, and indemnification from both the company and the underwriters. This filing provides transparency on the terms of the debt issuance and the associated legal documentation.
COLGATE PALMOLIVE CO 8-K Report, Financial Results (Oct 31, 2025)
Colgate-Palmolive Company (CL) filed an 8-K on October 31, 2025, reporting on its financial results for the quarter ended September 30, 2025, via an attached press release. Investors should note the company is also providing updates on its previously disclosed Strategic Growth and Productivity Program. This program, approved in July 2025, aims to enhance growth and support its 2030 strategy through organizational alignment, supply chain optimization, and cost reduction. The company anticipates cumulative pre-tax charges between $200 million and $300 million related to this program, with a significant portion (75% to 85%) expected to involve cash expenditures and substantially all charges incurred by the end of 2028. The charges are primarily composed of employee-related costs and asset-related charges, with a global distribution across various geographical segments and its Hill's Pet Nutrition business.
COLGATE PALMOLIVE CO 8-K Report, Financial Results (Aug 1, 2025)
Colgate-Palmolive Company (CL) has filed an 8-K report highlighting two key events. The first pertains to the release of their earnings for the second quarter ended June 30, 2025, as detailed in a press release attached as an exhibit. While specific financial figures from this press release are not detailed within the 8-K text itself, this filing serves as notification to investors about the availability of this crucial quarterly performance data. The second, and more significant, announcement details the approval of a new three-year "Productivity Program" by the Board of Directors. This program, effective immediately and extending through 2028, aims to enhance future growth by optimizing the global supply chain, streamlining organizational structure, and reducing overhead costs. The company anticipates cumulative pre-tax charges between $200 million and $300 million to be recognized over the program's duration, primarily recorded in the Corporate segment and not impacting internal segment operating performance metrics.
COLGATE PALMOLIVE CO 8-K Report, Executive Changes (May 29, 2025)
Colgate-Palmolive Company (CL) announced a significant executive appointment and a planned retirement, signaling strategic shifts in its leadership. The company has appointed Shane Grant as its new Chief Operating Officer, Americas, effective June 16, 2025. Mr. Grant brings extensive international experience from leadership roles at Danone and The Coca-Cola Company, most recently serving as Group Deputy CEO and CEO Americas at Danone. In addition, Prabha Parameswaran, currently Group President, Growth and Strategy, will transition to Vice Chair effective June 16, 2025, ahead of her planned retirement on October 1, 2025. The company has also made other executive promotions, including Panagiotis Tsourapas to Chief Operating Officer, Europe, Asia Pacific, Africa Eurasia, Skin Health & Global Customer Development, and John Hazlin to Chief Growth Officer, both effective June 16, 2025. These appointments suggest a focus on strengthening regional operations and driving global growth initiatives.
View all 8-K filings →